OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC - OBI Pharma 台灣浩鼎 OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. TAIPEI, Taiwan, May 1, 2025 — OBI Pharma, Inc. （“OBI”）, a clinical stage oncology company （4174.TWO）, today...

🔔U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology.
#ADC #GlycOBI #Trop2 #OBIPharma #INDClearance

Learn more:
www.obipharma.com/news/obi-pha...

Antag Therapeutics secures €80 million in weight loss therapy financing - PharmaTimes Versant Ventures leads investment round to advance drug

#AntagTherapeutics #Antag #weightlosstherapy #VersantVentures #drugdevelopment #SeriesAfinancing #AT7687 #obesity #NovoHoldings #SROne #DawnBiopharma #Pictet #INDclearance #GlucoseDependentInsulinotropicPolypeptideReceptor #InvestigationalNewDrugapplication
pharmatimes.com/news/antag-t...